DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis

Information source: Linkoeping University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fatigue; Radicular Pain; Cognitive Dysfunction; Paresthesia; Paresis

Intervention: Doxycycline (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Linkoeping University

Official(s) and/or principal investigator(s):
Pia Forsberg, MD, Principal Investigator, Affiliation: Department of Infectious Diseases, Faculty of Health Sciences, Linköping university, Sweden


The aim of this randomised, double-blind crossover study was to determine whether Doxycycline has an impact on the persistent symptoms post-neuroborreliosis, through alterations in the immune response and whether such an effect could influence the clinical outcome.

Clinical Details

Official title: Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Primary outcome: Improvement in persistent symptoms

Secondary outcome: Changes in cytokine levels in plasma/serum in patients during treatment with DOX/PBO

Detailed description: Persistent symptoms after treatment of neuroborreliosis (NB) are not uncommon. There is currently no evidence for improvement of symptoms after repeated or prolonged antibiotic treatment. However, clinical observations have indicated that some patients improve during treatment with doxycycline (DOX), but regain the symptoms some time after completed treatment. This may be due to an immunomodulatory effect of the drug. The aim of this randomised, double-blind crossover study was to determine whether DOX has an impact on the persistent symptoms through alterations in the immune response and whether such an effect can influence the clinical outcome. A total of 15 patients from South-East Sweden with previously adequately diagnosed NB with diverse persistent symptoms ≥6months after antibiotic treatment were randomised in a double-blind, crossover fashion to receive either DOX 200 mg or placebo (PBO) once daily for three weeks, followed by a wash-out period of six weeks and a further three-weeks treatment with either DOX 200 mg or PBO once daily for three weeks. The primary outcome measures were improvement of the persistent symptoms and physical and mental health, evaluated using the visual analogue scale (VAS), the 36-item Short-Form General Health Survey (SF-36) and through physical examination with special emphasis on neurologic status at the follow-up visits. Secondary outcome measures were changes in drug-induced antigen-stimulated and unstimulated cytokine responses.


Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- a history of adequately diagnosed and treated neuroborreliosis (presence of

intrathecal borrelia-antibody production)

- persistence of symptoms (with debut in conjunction with neuroborreliosis) of typical

character, such as headache, radiculitis, cognitive dysfunction, fatigue, mood disorders, paresthesia or paresis > 6 months post-treatment of neuroborreliosis Exclusion Criteria:

- systemic immunosuppression (treatment with corticosteroids, cytostatics etc)

- ongoing infection at inclusion

- allergy against doxycycline

- pregnancy

- breast feeding

- psychiatric disease

- multiple sclerosis

- rheumatoid arthritis

- diabetes mellitus type 1 or II

- inflammatory systemic diseases

- liver ohc kidney dysfunction

- treatment with didanosine, quinapril, antacids

- malignancy

Locations and Contacts

Clinic for Infectious Diseases, University Hospital, Linköping, Östergötland 58185, Sweden
Additional Information

Starting date: February 2005
Last updated: September 17, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017